You are here

Share:

Vaccines and Methods of Treating Drug-Resistant HIV-1 and Hepatitis B Viruses

Summary
Researchers at the NCI have developed a method of lowering a viral load of a virus resistant to antiviral drugs. The inclusion of a synthetic peptide induces a cytotoxic T lymphocyte (CTL) response specific for cells infected with the antiviral drug-resistant virus. NCI seeks licensees or co-development partners for this invention.
NIH Reference Number
E-137-2003
Product Type
Keywords
  • HIV, Hepatitis B, peptide, cytotoxic T lymphocyte
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

This technology relates to methods for lowering a viral load of a virus where the virus causes a chronic viral infection and is resistant to an antiviral drug. The method comprises administering to a host a medicament comprising an antiviral drug to restrict the intracellular multiplication of the virus and that is capable of selecting for a predetermined antiviral drug-resistant mutation in a viral protein. The medicament further comprises a synthetic peptide that comprises the predetermined antiviral drug-resistant mutation and at least six amino acid residues flanking that mutation that are identical to the amino acid sequence of the viral protein of the antiviral drug-resistant virus. The synthetic peptide induces a cytotoxic T lymphocyte (CTL) response specific for cells infected with the antiviral drug-resistant virus. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved. Further, the compositions and methods of this technology are useful to target many viruses that can develop antiviral drug resistance, including HIV-1, HIV-2, hepatitis B virus, hepatitis C virus, and human herpesviruses.

Potential Commercial Applications
  • Therapeutic treatment using an antiviral drug in combination with a synthetic peptide for patients with viral infections
  • Treatment to induce immune response in patients with drug resistance viral infections
Competitive Advantages
  • Applicable to a wide variety of infectious diseases
  • Can be used in combination with antiviral drugs
Inventor(s)

Andrew T. Catanzaro, Jay A. Berzofsky (NCI)

Development Stage
Patent Status
  • U.S. Patent Issued: U.S. Patent Number 9,474,793, Filed 20 Aug 2007, Issued 25 Oct 2016
Therapeutic Area
Updated
Monday, December 10, 2018